Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pressure On Tecentriq: Bladder Cancer Heats Up With Opdivo Approval, Keytruda Filing

Executive Summary

Merck's filings in bladder cancer span first-line and second-line treatment and include overall survival data. Roche also is getting ready to move Tecentriq to the frontline setting.

Advertisement

Related Content

Keytruda/Chemo Combo Approval Means Merck Holds Crown, For Now
Bladder Cancer Market Wide Open As Tecentriq Fails Confirmatory 2L Trial
AstraZeneca's Imfinzi Debuts In Bladder Cancer With Combo Coming Soon
Keeping Track: US FDA Expands Indications For Roche Tecentriq, Lucentis, Approves Second Infliximab Biosimilar
Keeping Track: Xermelo, Odactra, Noctiva Approved; Second Submissions For Avelumab And Deutetrabenazine
NSCLC Momentum Goes To Merck And Roche, Bodes Well For Combinations
Keeping Track: A Blizzard Of Submissions And A Small Flurry Of Approvals
Merck's Keytruda Reaches Blockbuster Status, But Still Lags In Lung Cancer
Cautious Roche Stresses: 'It's Not Only About APHINITY'
Under Fire, Bristol Plans To Pick Up The IO Pieces

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098171

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel